BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation